Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2017
Price : $35 *
At a glance
- Drugs Linezolid (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections; Pneumonia
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms UGENT-LIMOP
- 15 Aug 2017 Status changed from recruiting to completed.
- 03 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
- 03 Jun 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.